Concepedia

Publication | Open Access

A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors

DOIFull Paper Access

189

Citations

34

References

2011

Year

Simon Pacey, Richard H. Wilson, Mike Walton, Martin Eatock, Anthea Hardcastle, Anna Zetterlund, Hendrik‐Tobias Arkenau, Javier Moreno‐Farre, Udai Banerji, Belle Roels,
Clinical Cancer Research

Abstract

The recommended phase II dose of 17-DMAG is 80 mg/m(2) weekly i.v.

References

YearCitations

Page 1